Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Open-label, 2-period, non-fasting study to evaluate the effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Female Volunteers

Trial Profile

A Single-Center, Open-label, 2-period, non-fasting study to evaluate the effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Venetoclax (Primary) ; Azithromycin
  • Indications Acute myeloid leukaemia; Breast cancer; Cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Oct 2018 New trial record
    • 27 Sep 2018 Results published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top